Comparison
GHRP-6 vs. Triptorelin
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Growth
Research other
CAS no.
87616-84-0
57773-63-4
Molecular weight
873.02 g/mol
1311.45 g/mol
Half-life
0.4 h
3 h
Sequence
His-D-Trp-Ala-Trp-D-Phe-Lys-NH2pGlu-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NH2Mechanism of action
GHRP-6
GHRP-6 is a high-affinity agonist of the growth-hormone secretagogue receptor 1a (GHSR-1a) — the same receptor later shown to bind the endogenous hormone ghrelin. The identification of GHRP-6 as a pharmacological anchor led to cloning of GHSR in 1996 and the discovery of ghrelin itself in 1999. GHRP-6 stimulates pituitary GH secretion via a pathway independent of GHRH and can be combined synergistically with GHRH. Via GHSR in the hypothalamus it additionally activates NPY/AgRP neurons, producing an orexigenic (appetite-stimulating) effect in animal models.
Triptorelin
Triptorelin binds with high affinity to the GnRH receptor in the pituitary. After initial stimulation of LH and FSH secretion (flare phase, about 1-2 weeks), receptor desensitisation follows with consecutive gonadotropin suppression. This results in a reversible chemical castration: in men testosterone, in women oestrogen suppression to the postmenopausal range.
Evidence base
Highest evidence
Human trial
Human RCT
Studies
4
4
of which in humans
2
4
Effects recorded
4
3
Open conflicts
1
0
Documented adverse events
2
3